Talk Evidence - post pandemic pruning, breast cancer screening, and orphan drugs
Medicine and Science from The BMJ
00:00
The European Regulation on Orphan Drugs
Cost has never been a part of the orphan drug designation, but they're rightly bringing it up because medical reasons are the most common reasons for bankruptcy. And I think, at least in the United States, the patient advocacy community representing kind of rare diseases is, you know, we need products approved. So there's the system problem of how we defined the condition that the indication of what is superior drug and what are the right pathway to get medication to people.
Play episode from 28:41
Transcript
